<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02911480</url>
  </required_header>
  <id_info>
    <org_study_id>OXB-001</org_study_id>
    <nct_id>NCT02911480</nct_id>
  </id_info>
  <brief_title>Assessment of Pharmacokinetics and Bioavailability of Carbon-14 ([14C])-Labelled Oxytocin</brief_title>
  <official_title>Assessment of Pharmacokinetics and Bioavailability of Carbon-14 ([14C])-Labelled Oxytocin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxytone Bioscience BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxytone Bioscience BV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed as a phase I multiple dose study to evaluate the
      pharmacokinetics and bioavailability of [14C]-labelled oxytocin in healthy women.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study/financial issues
  </why_stopped>
  <start_date type="Anticipated">April 2016</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics (PK) parameter for oxytocin: maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1, predose and at t=3, 7, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 minutes.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetics (PK) parameter for oxytocin: time to Cmax (tmax)</measure>
    <time_frame>Day 1, predose and at t=3, 7, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 minutes.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetics (PK) parameter for oxytocin: area under the plasma-concentration time curve (AUC)</measure>
    <time_frame>Day 1, predose and at t=3, 7, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 minutes.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetics (PK) parameter for oxytocin: terminal half-life (t1/2)</measure>
    <time_frame>Day 1, predose and at t=3, 7, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 minutes.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetics (PK) parameter for oxytocin: bioavailability (F)</measure>
    <time_frame>Day 1, predose and at t=3, 7, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 minutes.</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Women of Child Bearing Potential</condition>
  <arm_group>
    <arm_group_label>oxytocin intravenous 0.1 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 0.1 International Units (IU) intravenous (IV) oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin intravenous 1 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 1 IU IV oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin intravenous 10 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 10 IU IV oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin tablet 20 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 20 IU tablet oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oxytocin tablet 200 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 200 IU tablet oxytocin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <arm_group_label>oxytocin intravenous 0.1 IU</arm_group_label>
    <arm_group_label>oxytocin intravenous 1 IU</arm_group_label>
    <arm_group_label>oxytocin intravenous 10 IU</arm_group_label>
    <arm_group_label>oxytocin tablet 20 IU</arm_group_label>
    <arm_group_label>oxytocin tablet 200 IU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking women of child bearing potential (WOCBP)

          -  Body mass index (BMI) between ≥ 18.0 and ≤ 30.0 kg/m2

          -  Subject must voluntarily sign a written informed consent agreement approved by the
             Independent Ethics Committee (IEC) after explanation of the nature and objectives of
             the study and before any study specific procedure

          -  Subject must be in good physical and mental health as judged by the Investigator based
             on evaluation of medical and gynecological history, physical examination, clinical
             laboratory, ECG, and vital signs data

          -  Subject is willing and able to comply with all conditions and requirements of the
             study

        Exclusion Criteria:

          -  Lactation and/or pregnancy in the previous 6 months before screening, whichever is
             applicable

          -  Intention to become pregnant during the study or within 1 months after the follow up
             visit

          -  History of, or existing thromboembolic, cardiovascular or cerebrovascular disorder

          -  Treatment for any major psychiatric disorder in the previous 12 months or use of
             antidepressant medication before screening

          -  Any clinically significant abnormality following review of medical history, laboratory
             results and physical examination at screening as judged by the Investigator

          -  Conditions or disorders that might affect the absorption, distribution, metabolism or
             excretion of the study drugs

          -  Contraindications for the use of oxytocin

          -  Hypersensitivity to the active substances or to any of the excipients of the
             investigational product or reference therapy

          -  Present use or use within 30 days before the start of the study medication of one or
             more of the following medications: antihypertensive drugs, anti-coagulant therapy,
             medication that could affect myometrial contractility, sex steroids, prostaglandins
             and its analogues, inhalation anesthetics, vasoconstrictors/sympathomimetics and
             caudal anesthetics, vasopressin-like drugs

          -  Use of any prescribed or over-the-counter medication within 14 days before Day 1

          -  Administration of any other investigational drug within 3 months before Day 1 or
             participation in 3 or more clinical trials in the 10 months before Day 1

          -  Loss of more than 500 milliliters (mL) blood during the 3 months before Day 1, or
             intention to donate blood in the 3 months after completing the study

          -  Subjects with a positive test result for hepatitis B, hepatitis C, or human
             immunodeficiency virus (HIV) at screening

          -  Subjects with a history of alcohol or drug abuse or with a positive result at
             screening, for tests of alcohol intake or drugs of abuse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

